Skip to main content

Table 3 Subgroup analysis of BANCR expression and overall survival (OS) in cancer patients

From: High BANCR expression is associated with worse prognosis in human malignant carcinomas: an updated systematic review and meta-analysis

 

No. of studies

No. of patients

Pooled HR (95% CI)

Heterogeneity

      

Fixed

Random

I2(%)

P-value

Overall survival

10

1151

1.56 (1.35–1.81)

1.60 (1.19–2.15)

60

0.008

Cancer type

      

Digestive system

4

551

1.87 (1.40–2.50)

1.94 (1.38–2.73)

17

0.31

GC

1

184

1.51 (1.03–2.23)

1.51 (1.03–2.23)

–

–

ESCC

1

142

2.24 (1.05–4.76)

2.24 (1.05–4.76)

–

–

HCC

1

109

4.24 (1.32–13.61)

4.24 (1.32–13.61)

–

–

CRC

1

116

2.24 (1.22–4.11)

2.24 (1.22–4.11)

–

–

Non-digestive system

6

600

1.47 (1.24–1.74)

1.35 (0.86–2.13)

70

0.005

Respiratory system

1

113

0.5 (0.26–0.54)

0.5 (0.26–0.54)

–

–

NSCLC

1

113

0.5 (0.26–0.54)

0.5 (0.26–0.54)

–

–

Other system

5

487

1.59 (1.34–1.90)

1.61 (1.25–2.06)

15

0.32

BC

2

281

1.55 (1.29–1.87)

1.55 (1.29–1.87)

0

0.62

Osteosarcoma

1

84

2.93 (1.12–7.67)

2.93 (1.12–7.67)

–

–

retinoblastoma

1

60

2.90 (1.05–8.03)

2.90 (1.05–8.03)

–

–

ccRCC

1

62

0.77 (0.24–2.47)

0.77 (0.24–2.47)

–

–

Analysis method

 Univariate analysis

3

238

0.95 (0.66–1.37)

0.84 (0.41–1.75)

68

0.04

 Multivariate analysis

7

911

1.71 (1.47–2.02)

1.79 (1.47–2.18)

11

0.34

HR estimation method

 Indirectly

4

349

1.07 (0.76–1.52)

1.15 (0.52–2.56)

76

0.006

 Directly

6

802

1.69 (1.44–1.99)

1.69 (1.44–1.99)

0

0.49

number of patients

 more than 100

6

880

1.56 (1.33–1.82)

1.57 (1.07–2.31)

70

0.005

 less than 100

4

271

1.62 (1.11–2.35)

1.71 (1.01–2.90)

36

0.2

BANCR expression level

 high expression

8

976

1.68 (1.45–1.96)

1.71 (1.44–2.03)

6

0.38

 low expression

2

175

0.55 (0.31–0.96)

0.55 (0.31–0.96)

0

0.52

Quality scores

 Score = 9

8

973

1.54 (1.32–1.80)

1.61 (1.15–2.24)

64

0.007

 Score < 9

2

178

1.78 (1.04–3.06)

1.48 (0.53–4.11)

61

0.008

DFS

3

320

1.29 (0.91–1.82)

1.21 (0.33–4.41)

93

0.00001

RFS

1

216

1.53 (1.27–1.85)

1.53 (1.27–1.85)

–

–

  1. Note: BANCR BRAF-activated noncoding RNA; OS Overall survival; DFS: disease-free survival; PFS Progression-free survival; Random Random effects; Fixed Fixed effects; directly: HR was extracted directly from the primary articles; indirectly: HR was extracted indirectly from the primary articles; NSCLC Non-small cell lung cancer; HCC Hepatocellular carcinoma; CRC Colorectal cancer; BC Breast cancer; ccRCC Clear cell renal cell carcinoma; GC Gastric cancer; LNM Lymphatic node metastasis; DM Distant metastasis; HTS High tumor stage (III,IV);NA Not available; ESCC Esophagus cancer; directly: HR was extracted directly from article; OS Overall survival; DFS Disease free survival; RFS: recurrence free survival
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us